A supplier's sterilization capability is best understood as a set of documented responsibilities rather than a catalog of installed modalities. FDA guidance instructs reviewers to begin by locating the written agreement between the device manufacturer and the contract sterilizer, because validation obligations shift only where that agreement transfers them [1]. The supplier's technical value therefore rests on which duties it can assume — cycle development, dose audit, residue testing, release decisions — and how those duties appear in the device master record. Evaluating a potential partner starts with that allocation, then moves to the specific process controls and the evidence accompanying each claimed modality. This guide walks through those decision points and ends with a hypothetical assessment exercise that a quality team could adapt without inventing new testing.
Validation Boundaries Define the Actual Supplier Role
For a contract sterilizer, the validation objective under FDA's sterilization process controls applies only insofar as the written agreement assigns that responsibility to the contractor [1]. If the device maker retains cycle validation, the supplier's inspected duties narrow to controlling and monitoring the process, maintaining current procedures, and managing software and personnel qualifications that the manufacturer cannot observe directly [1]. A manufacturer that lacks detailed records about the contractor's software and staff must still assure adequacy through audits, site visits, or documentation review [1]. This makes the contract itself the first capability document to request.
The Compliance Policy Guide for contract sterilizers reinforces that allocation logic. The establishment that executes a given function is primarily responsible for the corresponding quality system regulation, and regulatory action after an inspection may reach one or both parties depending on performance [8]. Contract sterilizers must maintain complete batch records for operations they perform and work against written production and process specifications from the manufacturer [8]. A supplier that cannot produce these records during diligence is not merely administratively thin; it has failed to demonstrate the core separation that FDA treats as the basis for assigning accountability.
Modality Claims Reveal Less Than Process Boundary Conditions
Supplier materials list ethylene oxide, gamma, electron beam, X-ray, vaporized hydrogen peroxide, nitrogen dioxide, and moist heat among the technologies they handle [2][4]. Those lists communicate breadth, but the decision-relevant details are constraints attached to each process. Sterigenics describes EO as having wide material compatibility except for moisture- and temperature-sensitive materials, while gamma and e-beam share wide polymer compatibility with some oxidation limitations and differ on how quickly product can exit the facility [2]. STERIS AST lists VHP for implants, electronics-containing devices, pre-filled syringes, and temperature-sensitive products, and describes steam for heat-stable dry goods and sealed liquid containers [4].
Device design can override a modality's general appeal. Sterigenics notes that stored-energy devices such as pacemakers, insulin patch pumps, and connected neurostimulators should receive a full safety assessment before EO sterilization because of ignition concerns [2]. That assessment is presented through sister company Nelson Labs, not as an automatic property of the EO facility [2]. FDA's established method categories add a regulatory layer: dry heat, rigid-chamber EO, steam, gamma, electron beam, and vaporized hydrogen peroxide are listed as Category A with recognized consensus standards, while ozone and flexible-bag EO appear as Category B methods without FDA-recognized dedicated standards [3]. A supplier's claim to offer a method says nothing about which category the specific cycle falls into.
A Suggested Audit Exercise: Trace One Release Decision End to End
A quality team could structure a supplier capability review around a single hypothetical release decision for a gamma-sterilized syringe set. The exercise would ask the supplier to produce the written agreement defining which party owns validation, the current master list of approved documents, one periodic assessment of sterilization adequacy, the software validation records for the dose-control system, and the batch record showing the verification dose and release decision for a recent lot [1][6]. The team would then compare each document's revision to the manufacturer's Device Master Record.
The goal is not to test the cycle but to test whether the supplier's documented control state matches the manufacturer's records. Discrepancies between the supplier's approved procedure list and the DMR would indicate that monitoring and acceptance procedures are not being maintained as current revisions, which FDA explicitly directs inspectors to check [1]. This exercise is a suggestion for internal diligence, not a substitute for regulatory inspection, and it should be adapted to the device's actual modality and the responsibility split named in the governing contract.
Control Evidence Sits Separately From Validation Evidence
A validated process does not remove the need for routine verification. FDA instructs that monitoring and acceptance procedures on the shop floor must match the current approved revision in the Device Master Record, with a master list verifiable against that record [1]. For sterilization software, inspectors review requirements, validation protocol, validation activities, change controls, and results, challenging one software-driven system based on significance [1]. A supplier audit that focuses only on the initial cycle study skips the documents most likely to show drift between what was validated and what is being run.
Inspection reports must capture more than the method name. FDA requires identification of all sterilization processes used, the specific process covered, any standard the firm claims to follow, sterilization site locations, the division of responsibilities among contract testing labs, sterilizer, finished device manufacturer, packaging, and labeling, the sterility assurance level, and whether parametric release is used [1]. A capable supplier can produce this division-of-responsibilities map without hesitation. A supplier that hesitates is signaling that the boundary between its duties and the manufacturer's duties has never been formally drawn.
Release and Residue Duties Belong in the Same Evaluation
Sterility assurance is not only the cycle. FDA's primary specification for a sterilization process is the desired sterility assurance level, with sterilant residues and endotoxin levels listed as additional possible specifications [1]. For ethylene oxide, the agency's guidance on 510(k) sterility information points to established categories while noting that categorization can change over time, and sponsors are encouraged to contact FDA for updated information [3]. Pyrogen claims carry their own labeling constraint: FDA recommends stating that a device meets pyrogen limit specifications or is non-pyrogenic, rather than claiming pyrogen free, unless complete removal can be established [3].
Testing suppliers illustrate how release support expands capability beyond the sterilizer. NAMSA lists sterility testing, sterility validation, reprocessing validation, product release testing, EO residuals testing, and ISO 11137 verification dose and dose audits among the areas it can assist with [5]. It describes validation testing as a qualitative assay aimed at ensuring no living microorganisms remain after sterilization, and frames lot release testing as a step to verify sterility, packaging integrity, and compliance before distribution [5]. A device maker that hears only 'sterilization' from a prospective partner should ask explicitly whether residue testing, verification dose, and dose audit duties are in scope or routed elsewhere.
Sources & references
- Sterilization Process Controls | FDA · www.fda.gov
- Medical Device Sterilization Services | Sterigenics · sterigenics.com
- Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile · www.fda.gov
- Medical Device Sterilization | STERIS AST · www.steris-ast.com
- Rapid Medical Device Sterility Testing and Validation | NAMSA · namsa.com
- Inspection of Medical Manufacturers - 7382.850 · www.fda.gov
- Sterilization for Medical Devices | FDA · www.fda.gov
- CPG Sec. 100.550 Status and Responsibilities of Contract Sterilizers Engaged in the Sterilization of Drugs and Devices | FDA · www.fda.gov